Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisPharmacogenetics-based warfarin dosing in childrenClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationPharmacogenomics of hypertension and heart diseaseImpact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysisPharmacology of anticoagulants used in the treatment of venous thromboembolismEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Integration of genetic, clinical, and INR data to refine warfarin dosing.The transcriptional regulation of the human CYP2C genesGenetic risk factors for major bleeding in patients treated with warfarin in a community setting.Warfarin therapy: in need of improvement after all these years.Expectations, validity, and reality in pharmacogenetics.Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analysesWarfarin dosing in patients with impaired kidney functionPharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.Drug induced interstitial lung disease.Warfarin pharmacogenetics.Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Genotype and risk of major bleeding during warfarin treatment.Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.Pharmacogenomics: application to the management of cardiovascular diseaseCardiovascular pharmacogenomicsStakeholder perspectives on a risk-benefit framework for genetic testing.Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.Race influences warfarin dose changes associated with genetic factors.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan.Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.Genome-wide association study of warfarin maintenance dose in a Brazilian sample
P2860
Q26823542-4C083EC5-4F31-4149-BADD-4D14452F1981Q27002899-BD7A408C-1DA7-4DE1-8385-FCAF45E7BEB3Q27008320-00B71088-0A4C-4FDF-A3ED-EAD7A4363A01Q27008360-592F066A-EA25-4992-906E-429587FCE98BQ27011524-D52A1DEA-F681-4D9B-930C-BCB5FB061863Q27015722-388EF442-5E9F-40C6-B112-33BC098DC909Q28071310-65429911-4A89-439F-8DC4-1A7962224A3DQ28078967-0D6846B6-93F2-4217-B174-BEB5D1873BA2Q28276514-178500E7-086F-497E-87B7-EF73E9D9D06EQ33517162-4C36867C-5519-472E-8653-395D852D2F13Q33550741-24D671F7-D69D-4FBB-903C-6DBAE913B49EQ33597311-D6B43E1C-7354-4BA5-A61E-9E52C7EA7E4CQ33792352-F2BF8A7E-195A-4223-8161-C76112CF0918Q33793086-52ADDF37-79BA-47CE-81D3-F73C8C45B3EAQ33926313-3D3D7D0A-CBF0-4808-85E6-355A656E5BC3Q33943678-0D969398-3189-4674-825B-257296C38AA3Q33984240-5807398E-C844-4A4C-AC89-3E1E4D42370EQ33990359-D9DE2DDB-C67B-4460-A884-34B1AD0BB5C5Q33990441-50F25EFA-CBC3-42EF-9D18-5A834703D044Q34061511-7F2F4329-1E81-4648-B5C5-B0EA867AA5B2Q34078825-792B201B-CB49-495C-AB11-E6441F46BC32Q34238435-81E3BB68-143C-46F7-A8BF-30F15EE9CF97Q34402967-FF95E647-DBAA-4073-82D0-5C25677D740AQ34641494-1E2EA696-77C9-48A2-B7C4-D2EC1D9CC053Q34785072-5FD347F8-1B68-44FC-B3AF-FC3A6C1E2A0CQ34791041-59A5E6CC-E8F0-4A32-B485-9C758EFA4FC4Q35006973-A7C32AC5-AF78-4C73-A1D8-64730962549EQ35218128-03A538F3-A1A6-408B-A72C-03A501E30C17Q35309161-395345F8-0675-466B-BBC5-0A2B58637731Q35447163-C05B9439-1428-4D83-8AF4-BE029E907A96Q35546409-26F756D0-686D-4AFC-852A-03C3AE0869D0Q35553851-6C7F2782-EF27-49E4-B850-B106C051553EQ35772034-09F5E57D-5A85-4699-802D-70E82FE3D2C2Q35884265-5B034752-142E-4C66-AB11-9D5EF8061B70Q35888757-977A4D68-F4EA-4B09-89EF-A1C12A67A9ADQ35898150-A74BF391-3946-4671-954C-F0FF49809224Q35900767-6B3ACEC0-7A1B-488E-93DA-1B1E996E5140Q36017389-1ECDA0B5-4187-4ABF-A6D1-A9B24A4EAF1FQ36044022-7C5ED31A-C576-49BC-B63C-6D948D38D1F1Q36068687-0C436A84-5B2E-425C-9014-467ECB43C6F5
P2860
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 July 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@en
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@nl
type
label
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@en
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@nl
prefLabel
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@en
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@nl
P2093
P2860
P356
P1476
Influence of CYP2C9 and VKORC1 ...... American patients on warfarin.
@en
P2093
D K Arnett
J A Goldstein
T M Beasley
P2860
P304
P356
10.1038/SJ.CLPT.6100290
P407
P577
2007-07-25T00:00:00Z